Slovin, Susan <br/><br/>
Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  08 2019 
 - 4624-4633 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-18-3212  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abiraterone Acetate--administration & dosage<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics<br/>Benzamides--administration & dosage<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Isoindoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Patient Safety<br/>Prednisolone--administration & dosage<br/>Prostatic Neoplasms, Castration-Resistant--drug therapy<br/>Survival Rate<br/>Tissue Distribution<br/>Treatment Outcome